Status:
COMPLETED
Pilot Trial of Directly Observed Anti HCV Therapy & Contingency Management in a Population on Opiate Substitute Therapy
Lead Sponsor:
NHS Tayside
Collaborating Sponsors:
University of Dundee
Conditions:
Hepatitis C
Eligibility:
All Genders
Phase:
NA
Brief Summary
DOT-C is a cluster randomised trial of a pharmacist-led, directly observed anti HCV therapy pathway versus the conventional care pathway within community pharmacies. The primary trial outcome is to ev...
Detailed Description
DOT-C is a cluster randomised trial of a pharmacist-led, directly observed anti HCV therapy pathway versus the conventional care pathway within 8 community pharmacies. Patients attending an individual...
Eligibility Criteria
Inclusion
- HCV PCR positive to genotype 1
- On Opioid Substitution Therapy dispensed and with supervised administration by pharmacist
Exclusion
- HCV PCR positive to any genotype other than genotype 1
- Evidence of current or previous decompensated liver disease
- HIV infection
- HBsAg positive with detectable HBV DNA
- Aggressive or violent behaviour
- Inability to provide informed consent
- Pregnancy or breast feeding
Key Trial Info
Start Date :
November 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2016
Estimated Enrollment :
152 Patients enrolled
Trial Details
Trial ID
NCT03483818
Start Date
November 1 2015
End Date
November 1 2016
Last Update
March 30 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ninewells Hospital
Dundee, Tayside, United Kingdom, DD1 9SY